Loop Capital analyst Cody Acree raised his price target on Texas Instruments to $145 and kept his Buy rating, saying its Q4 results showed "signs of stabilization" across most end markets. The analyst notes that the results and sentiment for the company are now in line with the "vast majority" of analog/embedded chip sector, which appears to be in the early stages of an industry-wide cyclical recovery that he had been "predicting for the last several months". Acree believes that investors should buy the softer response in Texas Instruments stock price following the results.

Baird raised the firm's price target on Texas Instruments to $175 from $125 and keeps a Neutral rating on the shares. The firm said any unexpected/incremental softening in demand would likely trigger price cuts given the current environment of low lead times and excess capacity, and the shape of 2H recovery will be critical in addressing inventory levels.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

TD Cowen analyst Joshua Buchalter raised the firm's price target on Texas Instruments to $175 from $160 and keeps a Hold rating on the shares. The firm said the print wasn't great but an important improvement and positive indicator on stability for the group. That said, numbers still need to move meaningfully higher to build medium-term valuation support or material buyback growth.

BofA raised the firm's price target on Texas Instruments (TXN) to $190 from $175 and keeps a Neutral rating on the shares. TI's small Q1 beat and inline but sequentially rising Q2 sales guidance, "while modest, potentially marks a recovery inflection in industrial chip demand," with positive read-across for U.S. peers such as Analog Devices (ADI), Microchip (MCHP), NXP Semiconductors (NXPI) and On Semiconductor (ON), the analyst tells investors. However, despite an expected recovery, TI's sustained high capex intensity could keep reported calendar year 2024-26 pro-forma EPS below $6 per share, the analyst added.